Cheaper generic breast cancer drug put to the test

NCT ID NCT07493291

Ongoing Disease control Sponsor: Al-Mustansiriyah University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares the brand-name drug Ibrance (palbociclib) with a local generic version in 100 Iraqi women with stage IV hormone receptor-positive, HER2-negative breast cancer. The goal is to see if the generic works just as well and is as safe as the brand. Patients take the drug along with standard hormone therapy, and researchers track how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: palbociclib (brand-name Ibrance vs generic)
What this could lead to: If the generic works as well as the brand, it could offer a more affordable treatment option for advanced breast cancer patients.
What could go wrong: This is a small, single-country study with 100 patients, so results may not apply broadly. Generic formulations may vary in quality or effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREST CANCER CDK4/6 INHIBITOR

Contacts and locations

Locations

Anbar cancer center

Ramadi, Al-Anbar Governorate, 10003, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.